This small clinical discovery trial of preoperative HER2-positive breast cancer confirmed previous reports that dual-targeted anti-HER2 therapy was more effective at inducing pCR than single-agent therapy [10-12]. This evidence concerns the gene ERBB2 and breast cancer.